Loading
CM
Cantel Medical Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by EVNIN ANTHONY B, was filed 27 Mar 2020.
Cantel Medical Corp: what insiders have been doing
Cantel Medical Corp belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Cantel Medical Corp. The previous disclosure was published on 2 June 2021.
The full history, which starts in 2006, counts 56 purchases against 638 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
1,820
Thresholds
n/a
Buy Volume
€2M
56 ops. · all time
Sell Volume
€61M
638 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended July 2020 · cache
Income statement
Gross profitUS$375.4M
Net incomeUS$11.8M
Last declaration on 2 June 2021
Declarations1,820 total
134,724 shares@ US$80.5977.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075853:1
374,112 shares@ US$80.599.7% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075844:1
185,928 shares@ US$80.594.8% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075844:2
29,430 shares@ US$80.590.8% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075844:3
1,000 shares@ US$80.590.2% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075855:1
98,030 shares@ US$80.5917.6% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075855:2
16,036 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075857:0
12,216 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075845:0
12,132 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075850:0
57,585 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075839:0
59,288 shares@ US$80.5997.1% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075849:0
10,566 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075846:0
2,865,637 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075844:0
434,505 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075855:0
3,890 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075859:0
22,970.431 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075863:0
41,622 shares@ US$80.5998.1% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075864:0
13,953 shares@ US$80.5997.8% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075843:0
4,159 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075840:0
4,400 shares0Common Stock, par value $.10 per shareSEC:0001104659-21-075853:0
1,935 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075860:0
7,570 shares@ US$80.59100.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075852:0
794 shares@ US$83.481.9% of flowCommon Stock, par value $.10 per shareSEC:0000019446-21-000021:0
301 shares@ US$83.402.2% of flowCommon StockSEC:0000019446-21-000019:0
1,637 shares@ US$88.182.9% of flowCommon StockSEC:0000019446-21-000017:0
25 of 1820 declarations
About Cantel Medical Corp
Cantel Medical Corp. (ticker: CMD) was a U.S.-based healthcare company focused on infection prevention and medical-device reprocessing. It was historically listed on the NASDAQ before being acquired by STERIS, with the transaction completed in June 2021. For French-speaking investors in France, Belgium and Switzerland, Cantel is best understood as a former listed medtech specialty name whose operating footprint and product know-how were folded into a larger U.S. healthcare platform.
The company was founded in 1963 in Little Falls, New Jersey, and built its franchise around products and services designed to reduce infection risk in clinical and life-science settings. Its historical headquarters were in the United States, and over time it expanded through a mix of organic growth and acquisitions. Cantel strengthened its portfolio through deals that added capabilities in endoscopy, water purification, and dental infection-control solutions, giving it a diversified but highly specialized position in healthcare hygiene and reprocessing.
Read moreShow less
Prior to the STERIS acquisition, Cantel reported four operating segments: Medical, Life Sciences, Dental and Dialysis. That structure captured its exposure to healthcare procedures, laboratory environments and other settings where contamination control is mission-critical. Its core offering included medical-device reprocessing systems, disinfectants, detergents, cleaning and disinfection consumables, and water purification and filtration solutions. In endoscopy, in particular, Cantel was recognized for equipment and consumables used to clean and disinfect flexible endoscopes and related reusable devices.
From a competitive standpoint, Cantel occupied a defensible niche. Demand was supported by recurring regulatory requirements, patient-safety standards and the constant need for hospitals, clinics and labs to comply with strict hygiene protocols. The business model combined installed equipment, recurring consumables and technical services, which typically creates a relatively resilient revenue base and meaningful customer switching costs.
The most important recent corporate event was the company’s integration into STERIS, a U.S. company listed on the NYSE, which completed the acquisition in 2021. As a result, CMD is no longer an independent public stock, but the assets and product lines that once belonged to Cantel continue inside a much larger global sterilization and infection-prevention platform. In market terms, Cantel should therefore be viewed as a former U.S. NASDAQ-listed healthcare specialist whose legacy remains relevant through STERIS’s broader business mix.
